Viatris (VTRS) Receivables (2019 - 2026)
Viatris' (VTRS) quarterly Receivables came in at $3.6 billion in Q1 2026, down 2.49% year-on-year from $3.7 billion in Q1 2025, and up 2.59% quarter-over-quarter from $3.5 billion in Q4 2025.
Viatris (VTRS) Receivables (2019 - 2026) Analysis & Trends
Viatris' Receivables history runs 8 years deep, the most recent figure standing at $3.6 billion for Q1 2026.
- On a quarterly basis, Receivables fell 2.49% year-over-year to $3.6 billion in Q1 2026; TTM through Mar 2026 was $3.6 billion, a 2.49% decrease from a year earlier, with the FY2025 full-year figure at $3.5 billion, down 7.49% from the prior year.
- Receivables improved to $3.6 billion in Q1 2026 per VTRS's latest filing, from $3.5 billion in the prior quarter.
- Across five years, Receivables topped out at $4.6 billion in Q1 2022 and bottomed at $3.5 billion in Q4 2025.
- The 5-year median for Receivables is $4.1 billion (2023), against an average of $4.1 billion.
- Across the five-year window, Receivables retreated 20.86% in 2022 and rose 12.61% in 2024, its largest moves.
- Year by year, Receivables stood at $4.4 billion in 2022, then gained by 4.37% to $4.6 billion in 2023, then declined by 17.69% to $3.8 billion in 2024, then declined by 7.49% to $3.5 billion in 2025, then rose by 2.59% to $3.6 billion in 2026.
- Per Business Quant, the three latest VTRS Receivables figures stand at $3.6 billion (Q1 2026), $3.5 billion (Q4 2025), and $3.8 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 2.99 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 3.39 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 1.51 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 6.46 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 312.00 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 15.29 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 3.58 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 768.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 1.15 Bn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 2.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.58 Bn |
| Dec 31, 2025 | 3.49 Bn |
| Sep 30, 2025 | 3.83 Bn |
| Jun 30, 2025 | 3.72 Bn |
| Mar 31, 2025 | 3.67 Bn |
| Dec 31, 2024 | 3.77 Bn |
| Sep 30, 2024 | 4.58 Bn |
| Jun 30, 2024 | 4.45 Bn |
| Mar 31, 2024 | 4.47 Bn |
| Dec 31, 2023 | 4.58 Bn |
| Sep 30, 2023 | 4.25 Bn |
| Jun 30, 2023 | 4.09 Bn |
| Mar 31, 2023 | 3.97 Bn |
| Dec 31, 2022 | 4.39 Bn |
| Sep 30, 2022 | 3.84 Bn |
| Jun 30, 2022 | 4.29 Bn |
| Mar 31, 2022 | 4.63 Bn |
| Dec 31, 2021 | 4.76 Bn |
| Sep 30, 2021 | 4.85 Bn |
| Jun 30, 2021 | 5.08 Bn |